The company is developing an anonymized, deidentified data platform that will be used to gain clinical insights and discover new treatments. The tool will be offered to tech, biopharma and other healthcare companies.
“Culmination Bio was built to expand on the success of Intermountain’s precision medicine efforts by creating longitudinal, multimodal data sets,” said Lincoln Nadauld, MD, PhD, CEO of Culmination and a former vice president and chief of precision health at Intermountain, in a March 17 news release. “Culmination’s powerful insights platform will unlock the next generation of discoveries to advance healthcare.”
Intermountain Ventures, the health system’s venture capital arm, helped propel the new company.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
